1. AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair

   • Lilach Moyal
   • Neta Goldfeiz
   • Emmilia Hodak

   PRECLINICAL STUDIES 08 September 2017 Pages: 1 - 9

   

2. CUDC-907, a dual HDAC and PI3K inhibitor, reverses platinum drug resistance

   • Kenneth K. W. To
   • Li-wu Fu

   PRECLINICAL STUDIES 17 August 2017 Pages: 10 - 19

   

3. Crucial microRNAs and genes in metformin’s anti-pancreatic cancer effect explored by microRNA-mRNA integrated analysis

   • Yilong Li
   • Le Li
   • Bei Sun

   PRECLINICAL STUDIES 05 September 2017 Pages: 20 - 27

   

4. The kinesin Eg5 inhibitor K858 induces apoptosis and reverses the malignant invasive phenotype in human glioblastoma cells

   • Ludovica Taglieri
   • Giovanna Rubinacci
   • Susanna Scarpa

   PRECLINICAL STUDIES 30 September 2017 Pages: 28 - 35

   

5. A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors

   • Janice M. Mehnert
   • Gerald Edelman
   • Patricia M. LoRusso

   PHASE I STUDIES 17 April 2017 Pages: 36 - 44

   

6. Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non–small cell lung cancer

   • Satoshi Igawa
   • Sakiko Otani
   • Noriyuki Masuda

   PHASE I STUDIES 02 May 2017 Pages: 45 - 52

   

7. A phase Ib study of everolimus combined with metformin for patients with advanced cancer

   • Remco J. Molenaar
   • Tim van de Venne
   • Johanna W. Wilmink

   PHASE I STUDIES Open access 15 June 2017 Pages: 53 - 61

   

8. Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials

   • Jean-Marie Michot
   • Lina Benajiba
   • Vincent Ribrag

   PHASE I STUDIES 09 June 2017 Pages: 62 - 74

   

9. A Phase I study to determine safety, pharmacokinetics, and pharmacodynamics of ANF-RHO™, a novel PEGylated granulocyte colony-stimulating factor, in healthy volunteers

   • Hemant Misra
   • John Berryman
   • Abraham Abuchowski

   PHASE I STUDIES 28 July 2017 Pages: 75 - 84

   

10. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors

    • Glen J. Weiss
    • Gayle Jameson
    • Ramesh K. Ramanathan

    PHASE I STUDIES 20 July 2017 Pages: 85 - 95

11. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma

    • Glen J. Weiss
    • Lisa Blaydorn
    • Vivek Khemka

    PHASE II STUDIES 08 November 2017 Pages: 96 - 102

    

12. A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma

    • Sandra P. D’Angelo
    • Omid A. Hamid
    • Richard D. Carvajal

    PHASE II STUDIES 11 November 2017 Pages: 103 - 113

    

13. Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis

    • Xin Liu
    • Huijie Wang
    • Zhiguo Luo

    PHASE II STUDIES 23 November 2017 Pages: 114 - 120

    

14. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads

    • Joanna C. Masters
    • Dana J. Nickens
    • Michael Amantea

    REVIEW 13 October 2017 Pages: 121 - 135

    

15. Ganoderic acid, lanostanoid triterpene: a key player in apoptosis

    • Balraj Singh Gill
    • Navgeet
    • Sanjeev Kumar

    REVIEW 28 October 2017 Pages: 136 - 143

    

16. A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event

    • Francesco Gelsomino
    • Giovanni Vitale
    • Andrea Ardizzoni

    SHORT REPORT 20 June 2017 Pages: 144 - 146

17. Chemotherapy-induced cardiomyopathy caused by Pemetrexed

    • Takuya Oyakawa
    • Kei Iida
    • Takashi Sugino

    SHORT REPORT 28 June 2017 Pages: 147 - 150

    

18. Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy

    • Seiko Bun
    • Kan Yonemori
    • Kenji Tamura

    SHORT REPORT 21 July 2017 Pages: 151 - 155

    

19. Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers

    • Marie Bréchon
    • Marie Dior
    • Romain Coriat

    SHORT REPORT 01 August 2017 Pages: 156 - 162

    

20. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing

    • Kyoungmin Lee
    • Changhoon Yoo
    • Baek-Yeol Ryoo

    SHORT REPORT 07 August 2017 Pages: 163 - 169

    

21. Acknowledgement of Reviewers 2017

    ACKNOWLEDGEMENTS 29 January 2018 Pages: 170 - 170